ACE-031 vs CJC-1295.

ACE-031 (ramatercept) is not a peptide but a recombinant fusion protein that joins the extracellular domain of the human activin receptor type IIB (ActRIIB) to the Fc region of IgG1. Developed by Acceleron Pharma, it works as a ligand trap that soaks up myostatin and related TGF-beta-family proteins that normally restrain muscle growth. It was engineered as a candidate therapy for muscle-wasting conditions, most prominently Duchenne muscular dystrophy (DMD). Unlike most compounds grouped with muscle peptides, it genuinely reached human clinical trials before its development was stopped.

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), based on the first 29 amino acids of human GHRH (GRF 1-29) with several amino-acid substitutions that resist enzymatic degradation. The name is used for two distinct molecules: "CJC-1295 with DAC," which carries a Drug Affinity Complex (a maleimidoproprionic acid linker) that covalently binds to circulating albumin to dramatically prolong its action; and "CJC-1295 without DAC" (often sold as "modified GRF 1-29" or "Mod GRF 1-29"), which lacks the albumin-binding linker. It was originally developed by the Canadian biotech company ConjuChem as an investigational therapeutic.

ActRIIB is a receptor through which myostatin (GDF-8), activins, and several other TGF-beta-superfamily ligands signal to limit skeletal muscle mass. By presenting a soluble decoy receptor, ACE-031 binds these ligands in the circulation and prevents them from activating ActRIIB on muscle, releasing the brake on muscle growth. Because the trap captures multiple ligands beyond myostatin, including some that act on blood vessels, it produces effects outside muscle as well. This mechanism was established in animal models and then probed directly in humans.

As a GHRH analog, CJC-1295 binds the GHRH receptor on somatotroph cells of the anterior pituitary, activating Gs-protein/cAMP/PKA signaling to stimulate synthesis and pulsatile release of endogenous growth hormone (GH), which in turn raises hepatic insulin-like growth factor 1 (IGF-1). The four substitutions in the GRF(1-29) backbone (notably at the position-2 alanine that is the dipeptidyl peptidase-IV cleavage site) protect the peptide from rapid breakdown, extending the half-life of the non-DAC form to roughly 30 minutes versus minutes for native GHRH. In the DAC version, the maleimide linker forms a covalent bond with cysteine-34 of serum albumin, creating a long-circulating depot; because it raises GH in a more sustained rather than sharply pulsatile manner, it is described as increasing trough and mean GH while largely preserving the body's own pulse pattern.

ACE-031 has genuine human data. Attie et al. reported a single ascending-dose study in healthy postmenopausal women in Muscle & Nerve (2013, PMID 23169607), observing increases in lean mass and biomarker changes consistent with myostatin inhibition. That was a phase 1 design: a small, single-administration, dose-escalating study in a narrowly selected healthy population, sponsored by the developer Acceleron Pharma, with imaging and biomarker endpoints rather than measures of function, and without the duration needed to detect anything that emerges over months. Campbell et al. published the randomized, placebo-controlled trial in ambulatory boys with DMD in Muscle & Nerve (2017, PMID 27462804), which showed trends toward preserved 6-minute-walk distance, higher lean mass and bone mineral density, and lower fat mass, but was stopped early. Because the trial was terminated before completing enrollment and follow-up, the walking-distance result remained a trend rather than a demonstrated benefit, the study lost the statistical power it had been designed with, and no confirmatory trial was ever run. Every efficacy statement about ACE-031 therefore rests on an interrupted study. This places ACE-031 well beyond the preclinical status of most muscle compounds, even though it never demonstrated confirmed clinical efficacy. The wider myostatin-pathway field has repeated the same pattern. Domagrozumab, an anti-myostatin antibody, failed its primary endpoint in Duchenne muscular dystrophy. Bimagrumab, an ActRII-blocking antibody, has produced consistent increases in lean mass without delivering the functional outcomes originally sought, and its cardiac safety has been examined separately in older adults (PMID 41873146). Increasing muscle mass has proven considerably easier than improving what patients can actually do. For ACE-031 specifically there is no chronic exposure data, no published long-term follow-up of the participants who were treated, no completed outcome trial, and no development activity after the early 2010s from which to draw further evidence.

The principal human evidence is a single 2006 Phase 1 study in healthy adults by Teichman et al. (J Clin Endocrinol Metab, PMID 16352683), which reported that one subcutaneous dose of CJC-1295 with DAC produced dose-dependent increases in mean plasma GH of roughly 2- to 10-fold for 6 days or more and IGF-1 increases of about 1.5- to 3-fold for 9-11 days, with an estimated half-life of 5.8-8.1 days and IGF-1 staying above baseline up to 28 days after repeated dosing. ConjuChem advanced the DAC compound into a Phase 2 trial in HIV-associated visceral obesity (ClinicalTrials.gov NCT00267527), but that 12-week trial was terminated in 2006. Beyond these, robust controlled human efficacy and long-term safety data are essentially absent; there are no large or long-term trials, no published outcomes for the non-DAC "modified GRF 1-29" form in humans, and much of the mechanistic rationale rests on GHRH-class pharmacology rather than direct trials of this molecule. Claims about body composition, recovery, or anti-aging benefit are not supported by published controlled human outcome data.

The DMD program was halted in 2011 for safety reasons. Investigators observed dose-related, non-muscle vascular effects, specifically epistaxis (nosebleeds), gum bleeding, and telangiectasias (small dilated skin vessels), attributed to the trap's activity on additional TGF-beta-family ligands. The mechanistic explanation is that a soluble ActRIIB decoy does not bind myostatin alone: it also sequesters activins and bone morphogenetic proteins that help maintain vascular integrity, so the bleeding signal is a predictable consequence of the trap's breadth rather than an idiosyncratic reaction. These events appeared in children being treated for a serious progressive disease, the population most willing to accept risk for benefit, and they were still judged unacceptable. Acceleron and its partner Shire ended the collaboration and did not restart development. Short-term human exposure is documented, but the compound was discontinued precisely because of these off-target vascular signals, and long-term safety was never established. There is no chronic dosing data, no published long-term follow-up of the boys who were exposed, and no immunogenicity or reproductive toxicology in the public record. Later programs targeting the same pathway were deliberately engineered for narrower ligand selectivity in order to avoid this exact problem. Anything sold online under the ACE-031 name is an unapproved recombinant protein produced outside pharmaceutical manufacturing controls, where identity, glycosylation, aggregation state, and endotoxin content are all unverified, and aggregated Fc-fusion proteins carry their own immunogenicity risk. The monitoring a real trial would demand, including vascular and bleeding assessment, dermatologic examination, and anti-drug antibody testing, does not exist outside a clinical setting.

In the short Phase 1 work, CJC-1295 with DAC was described as generally well tolerated, with the kinds of effects expected from GHRH-class agents (e.g., injection-site reactions, flushing, headache); however, this reflects small numbers and short follow-up. The Phase 2 HIV trial (NCT00267527) was terminated in 2006, and a participant death during the program drew scrutiny, though available reporting attributed that death to pre-existing coronary disease rather than establishing causation by the drug; the episode underscores how thin the safety record is. Sustained elevation of GH/IGF-1 carries class-level theoretical concerns familiar from growth-hormone pharmacology, including fluid retention, joint/muscle pain, insulin resistance and elevated blood glucose, and a theoretical concern about promoting growth of existing malignancy; long-term safety in humans is simply unknown. Much material sold as "CJC-1295" online is from unregulated sources with no purity, sterility, or identity guarantees, adding contamination and mislabeling risks.

ACE-031 was never approved by the FDA or any other regulator, and its clinical development was terminated in the early 2010s after the DMD trial was stopped for safety. It is not a marketed drug and is not legitimately available for human use. Any product sold online as ACE-031 is unapproved research-grade material.

CJC-1295 (with or without DAC) has never been approved by the FDA or any major regulatory agency for any indication and remains an investigational compound that did not complete clinical development. It is not an approved medicine; it is sold only as a "research chemical," and GHRH analogs/GH secretagogues of this type are prohibited in sport by the World Anti-Doping Agency.